Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Researchers identify molecular pathway that improves ultrasound-based bone defect healing (opens in a new tab)

news-medical.net · 2026-10-15

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 3 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe article says the work was published in the International Journal of Oral Science on 14 September, 2026, and it names corresponding authors Professor Songlin Wang and Associate Professor Lei Hu.View evidenceHide evidence

As stated14 September, 2026

Why this verdict

The supplied abstract-level paper profile does not provide publication date, journal issue metadata, or corresponding-author names. Therefore the stated International Journal of Oral Science publication date of 14 September 2026 and the named corresponding authors cannot be verified from the provided profile.

Claim 2 of 4SupportedResearchers from Capital Medical University identified a CaN/NFATC3/Id3/E2A/Bmp4 signaling pathway that helps explain how low-intensity pulsed ultrasound (LIPUS) promotes bone regeneration.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the scientific substance: the paper reports Id3 downregulation during LIPUS-induced bone formation, functional Id3 effects on osteogenesis, ChIP-based Id3/E2A/Bmp-Smad mechanistic evidence, and integration into a CaN/NFATC3 → Id3 → E2A → Bmp4 pathway. The claim is causal but is framed as a mechanistic/basic-research explanation, which is consistent with the reported intervention and pathway evidence. The Capital Medical University affiliation is not independently verifiable from the supplied profile, but the pathway claim itself is supported.

1

Study evidence

RNA-seq and PCR array analyses reported significant downregulation of Id3 during LIPUS-induced bone formation.Described as significant downregulation; magnitude and quantitative metrics not provided in abstract.

“RNA sequencing and PCR array analyses revealed significant downregulation of Id3 during low-intensity pulsed ultrasound (LIPUS)-induced bone formation”
2

Study evidence

Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs, accompanied by upregulation of RUNX2 and OCN.

“Functional experiments demonstrated that Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs in vitro (upregulating RUNX2, OCN) … while Id3 overexpression reversed these effects.”
Claim 3 of 4SupportedId3 was identified as a molecular "brake" that limits LIPUS-induced osteogenesis and was significantly downregulated following ultrasound stimulation.View evidenceHide evidence

Why this verdict

The profile directly supports Id3 as a negative regulator or “brake” on LIPUS-induced osteogenesis: RNA-seq/PCR array evidence showed significant Id3 downregulation during LIPUS-induced bone formation, and functional experiments reported that Id3 knockdown enhanced while Id3 overexpression suppressed or reversed LIPUS-induced osteogenic effects in BMSCs and rodent defect models.

1

Study evidence

RNA-seq and PCR array analyses reported significant downregulation of Id3 during LIPUS-induced bone formation.Described as significant downregulation; magnitude and quantitative metrics not provided in abstract.

“RNA sequencing and PCR array analyses revealed significant downregulation of Id3 during low-intensity pulsed ultrasound (LIPUS)-induced bone formation”
2

Study evidence

Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs, accompanied by upregulation of RUNX2 and OCN.

“Functional experiments demonstrated that Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs in vitro (upregulating RUNX2, OCN) … while Id3 overexpression reversed these effects.”
Claim 4 of 4SupportedThe researchers developed an Id3 inhibitory peptide, rID3, which, when combined with LIPUS, enhanced osteogenesis and bone-defect healing in mice, suggesting a potential strategy for improving ultrasound-based bone regeneration.View evidenceHide evidence

Why this verdict

The profile supports development of an Id3-inhibitory peptide, rID3, targeting the Id3/E2A interface and reports that rID3 combined with LIPUS enhanced cranial bone defect healing in rodent models, with related in vitro and in vivo Id3-manipulation evidence supporting enhanced osteogenesis. The claim’s hedged translational wording is appropriate. At abstract depth, the supplied profile specifies rodent models rather than verifying the exact species as mice, and it lacks quantitative effect sizes or dosing details.

1

Study evidence

Engineered Id3-inhibitory peptide (rID3) targeting the Id3/E2A interface synergized with LIPUS to enhance cranial bone defect healing in rodent models.

“we engineered an Id3-inhibitory peptide (rID3) targeting the Id3/E2A interface, which would synergize with LIPUS to enhance defect healing of cranial bone.”
2

Study evidence

Id3 knockdown in vivo enhanced bone formation/defect healing in rodent bone defect models when combined with LIPUS.

“...and promoted in vivo bone formation in rodent bone defect models, while Id3 overexpression reversed these effects.”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

6 things the story did carry across
  • Id3 expression profiling showed significant downregulation during LIPUS-induced bone formation by RNA-seq/PCR array.
  • Functional in vitro BMSC experiments showed Id3 knockdown enhanced and Id3 overexpression suppressed LIPUS-induced osteogenic differentiation, including RUNX2/OCN marker changes.
  • In vivo rodent bone defect experiments showed Id3 manipulation modulated ultrasound-enhanced bone formation or defect healing.
  • Mechanistic evidence links Id3 to bHLH/E2A and Bmp/Smad signaling within a proposed CaN/NFATC3/Id3/E2A/Bmp4 pathway.
  • The paper engineered and tested rID3, an Id3-inhibitory peptide targeting the Id3/E2A interface, with LIPUS to enhance cranial bone defect healing in rodent models.
  • The evidence is preclinical, based on in vitro BMSC experiments and rodent bone-defect models, with no clinical human data reported in the abstract profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDevelop and test an Id3-inhibitory peptide (rID3) targeting the Id3/E2A interface as a combinatorial sonogenetic strategy with LIPUS to enhance cranial bone defect healing.in vivo animalExpand

In plain English

The authors engineered an Id3-inhibitory peptide (rID3) designed to disrupt the Id3/E2A interface and tested it as a combinatorial therapy with low-intensity pulsed ultrasound (LIPUS) in rodent cranial bone defect models. Reported findings indicate that rID3 plus LIPUS synergistically enhanced cranial defect healing in vivo, and the work frames this approach within a proposed CaN/NFATC3/Id3/E2A/Bmp4 mechanistic pathway for ultrasound-mediated osteogenesis.

Key findings

  • Engineered Id3-inhibitory peptide (rID3) targeting the Id3/E2A interface synergized with LIPUS to enhance cranial bone defect healing in rodent models.
“we engineered an Id3-inhibitory peptide (rID3) targeting the Id3/E2A interface, which would synergize with LIPUS to enhance defect healing of cranial bone.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroIdentify Id3 as a negative regulator (“brake”) of LIPUS/sonogenetics-mediated osteogenesis via expression profiling during ultrasound-induced bone formation.expression profiling (RNA-seq; PCR array validation)Expand

In plain English

RNA-seq and targeted PCR array expression profiling reported in the abstract show that Id3 transcript levels are significantly downregulated during low-intensity pulsed ultrasound (LIPUS)-induced bone formation, leading the authors to characterize Id3 as a putative negative regulator of ultrasound-mediated osteogenesis.

Key findings

  • RNA-seq and PCR array analyses reported significant downregulation of Id3 during LIPUS-induced bone formation.Described as significant downregulation; magnitude and quantitative metrics not provided in abstract.
“RNA sequencing and PCR array analyses revealed significant downregulation of Id3 during low-intensity pulsed ultrasound (LIPUS)-induced bone formation”
What this piece can’t prove
  • Downregulation is observational; causality requires intervention/functional validation beyond profiling data.
  • Unclear whether profiling was performed in vitro on BMSCs, ex vivo tissue, or in vivo samples, which affects generalizability to the stated setting.

1 further detail could not be confirmed from the summary.

3in vitroDemonstrate functionally that Id3 knockdown enhances and Id3 overexpression suppresses LIPUS-induced osteogenic differentiation in BMSCs in vitro.In vitro BMSC Id3 perturbation with LIPUSExpand

In plain English

In vitro experiments in bone marrow-derived mesenchymal stem cells (BMSCs) show that genetic knockdown of Id3 enhances LIPUS-induced osteogenic differentiation with upregulation of osteogenic markers RUNX2 and OCN, while Id3 overexpression reverses/suppresses these LIPUS-mediated effects.

Key findings

  • Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs, accompanied by upregulation of RUNX2 and OCN.
  • Id3 overexpression reversed or suppressed the LIPUS-enhanced osteogenic differentiation observed in BMSCs.
“Functional experiments demonstrated that Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs in vitro (upregulating RUNX2, OCN) … while Id3 overexpression reversed these effects.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vivo animalDemonstrate in vivo that Id3 manipulation modulates ultrasound-enhanced bone formation/defect healing in rodent bone defect models.in vivo animalExpand

In plain English

In rodent bone defect models, authors report that in vivo Id3 knockdown promotes bone formation/defect healing in the context of LIPUS, whereas Id3 overexpression reverses these effects.

Key findings

  • Id3 knockdown in vivo enhanced bone formation/defect healing in rodent bone defect models when combined with LIPUS.
  • Id3 overexpression in vivo reversed the bone-promoting effects seen with Id3 knockdown plus LIPUS.
“...and promoted in vivo bone formation in rodent bone defect models, while Id3 overexpression reversed these effects.”
What this piece can’t prove
  • Abstract lacks key methodological details for the in vivo experiments: animal species/strain, number of animals, defect type and size, exact LIPUS parameters, timing/dose of Id3 manipulation, and outcome measurement techniques.

2 further details could not be confirmed from the summary.

5in vitroEstablish a mechanistic pathway in which Id3 acts through bHLH (e.g., E2A) to inhibit Bmp/Smad signaling; supported by ChIP-based evidence.ChIP-based mechanistic assays (in vitro)Expand

In plain English

The abstract reports chromatin immunoprecipitation (ChIP) evidence that Id3 directly targets bHLH transcription factors (example given: E2A) and, in so doing, inhibits the Bmp/Smad osteogenic signaling cascade; the authors place this interaction within a proposed CaN/NFATC3 → Id3 → E2A → Bmp4 pathway.

Key findings

  • ChIP assays reported in the abstract indicate that Id3 directly targets bHLH transcription factors (example: E2A), and this interaction is associated with inhibition of the Bmp/Smad osteogenic signaling pathway.
“Chromatin immunoprecipitation (ChIP) assays confirmed that Id3 directly targets bHLH proteins to inhibit the Bmp/Smad pathway, a core cascade for osteogenesis.”
What this piece can’t prove
  • Evidence and methods are reported at abstract depth only; no experimental details are provided for ChIP (antibodies, controls, loci, replication, quantification).
  • The abstract does not report effect sizes, statistical significance, or numbers of biological replicates for the ChIP or pathway assays.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Zinc Oxide-Copper Sulfide Nanozyme Hydrogels for Bone Defect Repair by Modulating the Bone Immune Microenvironment and Promoting Osteogenesis/Angiogenesis

Crossref

Source (opens in a new tab)

And 9 more candidates considered.